ANGPTL1抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gasrtic cancer tissue using P00147(ANGPTL1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P00147(ANGPTL1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

ANGPTL1 (angiopoietin-like protein 1) is a secreted glycoprotein belonging to the angiopoietin-like family, which shares structural homology with angiopoietins but lacks the receptor-binding domain required for binding to Tie receptors. Primarily expressed in endothelial cells, liver, and placenta, ANGPTL1 is implicated in regulating angiogenesis, inflammation, and metabolic processes. Studies suggest it inhibits vascular endothelial growth factor (VEGF)-induced angiogenesis and modulates integrin signaling, influencing cell adhesion and migration. Its role in tumor suppression has gained attention, as ANGPTL1 is frequently downregulated in cancers, correlating with metastasis and poor prognosis. By suppressing epithelial-mesenchymal transition (EMT) and inhibiting metastatic spread, ANGPTL1 has emerged as a potential therapeutic target.

ANGPTL1 antibodies are essential tools for detecting and quantifying the protein in research settings. They enable investigations into its expression patterns, molecular interactions, and functional mechanisms in both physiological and pathological contexts. Commercially available antibodies—monoclonal or polyclonal—are widely used in techniques like Western blotting, immunohistochemistry, and ELISA. Recent preclinical studies explore therapeutic applications, such as antibody-based strategies to restore ANGPTL1 activity in cancers or block its interactions in metabolic disorders. However, challenges remain in optimizing specificity and understanding isoform diversity. Ongoing research aims to clarify its pleiotropic roles and validate its utility as a biomarker or therapeutic agent.